CA2609728A1 - Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases - Google Patents

Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases Download PDF

Info

Publication number
CA2609728A1
CA2609728A1 CA002609728A CA2609728A CA2609728A1 CA 2609728 A1 CA2609728 A1 CA 2609728A1 CA 002609728 A CA002609728 A CA 002609728A CA 2609728 A CA2609728 A CA 2609728A CA 2609728 A1 CA2609728 A1 CA 2609728A1
Authority
CA
Canada
Prior art keywords
polypeptide
betacellulin
insulin
composition
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002609728A
Other languages
English (en)
French (fr)
Inventor
Junyu Lin
Srinivas Kothakota
Ge Wu
Stephen Doberstein
Thomas Brennan
Lorianne Masuoka
Minmin Qin
Shannon Marshall
Yan Wang
Diane Hollenbaugh
Lewis T. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Five Prime Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2609728A1 publication Critical patent/CA2609728A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002609728A 2005-05-27 2006-05-30 Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases Abandoned CA2609728A1 (en)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US68570205P 2005-05-27 2005-05-27
US60/685,702 2005-05-27
US70196405P 2005-07-22 2005-07-22
US70149005P 2005-07-22 2005-07-22
US70206505P 2005-07-22 2005-07-22
US60/702,065 2005-07-22
US60/701,490 2005-07-22
US60/701,964 2005-07-22
US73379105P 2005-11-07 2005-11-07
US60/733,791 2005-11-07
US73686605P 2005-11-16 2005-11-16
US60/736,866 2005-11-16
US77816906P 2006-02-27 2006-02-27
US60/778,169 2006-02-27
US80044306P 2006-05-16 2006-05-16
US60/800,443 2006-05-16
US11/442,244 2006-05-30
US11/442,244 US20070054851A1 (en) 2005-05-27 2006-05-30 Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
PCT/US2006/020797 WO2006128125A2 (en) 2005-05-27 2006-05-30 Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases

Publications (1)

Publication Number Publication Date
CA2609728A1 true CA2609728A1 (en) 2006-11-30

Family

ID=37452973

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002609728A Abandoned CA2609728A1 (en) 2005-05-27 2006-05-30 Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases

Country Status (6)

Country Link
US (1) US20070054851A1 (enExample)
EP (1) EP1890722A2 (enExample)
JP (1) JP2008545715A (enExample)
AU (1) AU2006249327A1 (enExample)
CA (1) CA2609728A1 (enExample)
WO (1) WO2006128125A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010513321A (ja) * 2006-12-22 2010-04-30 ノヴェリクス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 少なくとも一種の上皮細胞増殖因子受容体特異抗体またはその誘導体を用いる糖尿病の治療
US9173991B2 (en) * 2007-07-02 2015-11-03 Roche Diabetes Care, Inc. Device for drug delivery
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
US20090147006A1 (en) * 2007-12-07 2009-06-11 Roche Diagnostics Operations, Inc. Method and system for event based data comparison
CN102139095A (zh) * 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
CN103124788B (zh) 2010-05-21 2016-01-13 梅里麦克制药股份有限公司 双特异性融合蛋白
AU2011257192A1 (en) * 2010-05-28 2013-01-10 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
WO2012012156A1 (en) * 2010-07-21 2012-01-26 Myomics, Inc. Methods and compositions for the improvement of skeletal muscle function in a mammal
CN102145164B (zh) * 2010-12-16 2013-02-27 深圳市健元医药科技有限公司 一种更加稳定的iapp类似物注射剂
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
EP3190418B1 (en) 2011-07-28 2019-05-01 metanomics GmbH Use of sm_sphingomyelin (d18:1, c16:0) as a marker for heart failure
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
CN108367051A (zh) * 2015-12-22 2018-08-03 雀巢产品技术援助有限公司 用于治疗肌肉减少症和虚弱的方法
KR101908056B1 (ko) 2017-05-25 2018-12-18 가천대학교 산학협력단 근아세포의 전기적 임피던스 모니터링 시스템 및 방법
EP4126000A1 (en) * 2020-03-31 2023-02-08 Universität Heidelberg Agents for use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases
WO2024253228A1 (ko) * 2023-06-09 2024-12-12 주식회사 메타파인즈 악액질 및 근손실의 예방 또는 치료용 조성물
EP4582080A1 (en) * 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof
WO2025170936A1 (en) * 2024-02-05 2025-08-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and methods for treating cardiac dysfunction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2099304T3 (es) * 1992-02-10 1997-05-16 Takeda Chemical Industries Ltd Mitogeno de la musculatura lisa y adn que lo codifica.
JP3945846B2 (ja) * 1995-11-09 2007-07-18 武田薬品工業株式会社 膵臓機能改善剤
DE69626034T2 (de) * 1995-11-09 2003-08-14 Takeda Chemical Industries, Ltd. Zusammensetzung für verbesserung der pankreasfunktion
ES2288034T3 (es) * 1998-12-09 2007-12-16 Takeda Pharmaceutical Company Limited Modificacion de betacelulina.
AU4209300A (en) * 1999-04-06 2000-10-23 Genentech Inc. Use of erbb receptor ligands in treating diabetes
DE60035192T2 (de) * 1999-04-26 2008-02-14 Applied Protein Sciences, LLC, Mountain View Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
US6815418B2 (en) * 1999-08-19 2004-11-09 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
AUPQ496900A0 (en) * 2000-01-06 2000-02-03 Gropep Pty Ltd Growth factor splice variant
CA2409996C (en) * 2000-05-23 2016-03-01 Cenes Pharmaceuticals, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US20040132679A1 (en) * 2002-09-03 2004-07-08 Baylor College Of Medicine Induction of pancreatic islet formation
JPWO2004050122A1 (ja) * 2002-12-04 2006-03-30 キッセイ薬品工業株式会社 高血糖症に起因する疾患の予防又は治療剤

Also Published As

Publication number Publication date
JP2008545715A (ja) 2008-12-18
WO2006128125A2 (en) 2006-11-30
EP1890722A2 (en) 2008-02-27
AU2006249327A1 (en) 2006-11-30
WO2006128125A3 (en) 2007-08-02
US20070054851A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
US20070054851A1 (en) Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
CN101166545B (zh) Glp-1聚乙二醇化的化合物
KR101238979B1 (ko) Ｐｅｇ화된 인슐린 리스프로 화합물
EP2764019B1 (en) Dual function proteins for treating metabolic disorders
KR102460198B1 (ko) 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제
US20060183677A1 (en) Novel exendin agonist formulations and methods of administration thereof
US7910548B2 (en) Methods for treating obesity
UA122692C2 (uk) Сполука-коагоніст рецепторів глюкагону та glp-1
EP3568149B1 (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
CN103249427A (zh) 速效胰岛素联合长效胰岛素
CA2875983A1 (en) Treatment of hypoglycemia
US20160002310A1 (en) Modified ingap peptides for treating diabetes
CA2592943A1 (en) Use of il-22 for the treatment of conditions of metabolic disorders
US20110319324A1 (en) Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
JP2025509433A (ja) ヒトインスリン類似体、その融合タンパク質及び医薬的使用
Wu et al. An overview of prospective drugs for type 1 and type 2 diabetes
US20160235810A1 (en) Methods of treating diabetes and related disorders
NZ794313A (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
HK1196383A (en) Dual function proteins for treating metabolic disorders

Legal Events

Date Code Title Description
FZDE Discontinued